Price$1.21+0.09 (+8.04%)
01:30 PM07:45 PM
News · 26 weeks31-80%
2026-04-192026-10-11
Mix2390d
- SEC Filings11(48%)
- Insider4(17%)
- Earnings3(13%)
- Dividends3(13%)
- Other2(9%)
Latest news
25 items- PRBioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual MeetingCARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that two abstracts detailing results from the Company’s ADDRESS-LC Phase 2 trial in Long COVID, and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson’s Disease have been accepted for presentation at ANA2026, the annual meeting of the American Neurological Association. Results of the two studies will be presented as posters during the conference. ANA2026 will be held in San Diego, CA from October 17-20, 2026. Long COVID — ADDRESS-LCTitle: Results of a Doub
- SECSEC Form DEF 14A filed by BioVie Inc.DEF 14A - BIOVIE INC. (0001580149) (Filer)
- PRBioVie Announces Topline Results from Phase 2 ADDRESS‑LC Trial Evaluating Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDStatistically significant benefits observed in bezisterim-treated Long COVID patients in pre-specified subgroups with high baseline fatigue, cognitive impairment, and/or post‑exertional malaise Bezisterim showed a consistent advantage over placebo on 21 out of 22 individual endpoints in the overall study population An estimated 17–20 million U.S. adults live with Long COVID and currently have no FDA‑approved treatment options Conference call scheduled for 8:30 a.m. today, September 15, 2026, to discuss results. CARSON CITY, Nev., Sept. 15, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for ne
- PRBioVie to Host Conference Call to Discuss Topline Data from Phase 2 ADDRESS-LC Trial and the Potential of Bezisterim in Long CovidCARSON CITY, Nev., Sept. 14, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the Company will host a conference call and webcast on Tuesday, September 15, 2026 at 8:30am ET to discuss topline results from its Phase 2 ADDRESS-LC trial (NCT06847191) evaluating its investigational drug candidate bezisterim, an oral drug that crosses the blood-brain barrier and is believed to reduce inflammation and improve insulin sensitivity, in Long COVID. Michael Peluso, MD, MHS, Associate Professor of Medicine, University of California, San Fr
- SECBioVie Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - BIOVIE INC. (0001580149) (Filer)
- SECSEC Form 424B5 filed by BioVie Inc.424B5 - BIOVIE INC. (0001580149) (Filer)
- PRBioVie Announces Update to Parkinson’s Phase 3 Development ProgramCARSON CITY, Nev., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced next stage of engagement with the Food and Drug Administration (FDA) to advance the Company’s Phase 3 development program evaluating bezisterim in Parkinson’s disease. "We are working closely with leading experts in Parkinson’s disease clinical development to finalize a Phase 3 trial design that includes MDS-UPDRS1 Part III as the primary endpoint, consistent with the FDA’s longstanding focus on motor symptom improvement in evaluating Parkinson’s therapies,
- PRBioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDCARSON CITY, Nev., Aug. 31, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ:BIVI) ("BioVie" or the "Company"), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that the last on-treatment visit of its ADDRESS-LC Phase 2 trial evaluating bezisterim for the treatment of neurological symptoms of Long COVID has been completed. The Phase 2 study is fully funded by a grant from the U.S. Department of War (DoW, formerly the U.S. Department of Defense). "With the last patient’s treatment visit completed, and the one-month virtual follow-up nearly complete, we anticipate announcing topline results for ADDRESS-LC before the e
- INSIDERChief Medical Officer Palumbo Joseph M bought $10,461 worth of shares (4,843 units at $2.16), increasing direct ownership by 406% to 6,036 units (SEC Form 4)4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERDirector Chappell Amy Suzon bought $1,570 worth of shares (727 units at $2.16) (SEC Form 4)4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERChief Financial Officer Kim Joanne Wendy bought $5,450 worth of shares (2,500 units at $2.18), increasing direct ownership by 266% to 3,441 units (SEC Form 4)4 - BIOVIE INC. (0001580149) (Issuer)
- INSIDERPresident & CEO Do Cuong V bought $31,637 worth of shares (15,210 units at $2.08), increasing direct ownership by 1,677% to 16,117 units (SEC Form 4)4 - BIOVIE INC. (0001580149) (Issuer)
- SECAmendment: SEC Form S-1/A filed by BioVie Inc.S-1/A - BIOVIE INC. (0001580149) (Filer)
- SECSEC Form 10-K filed by BioVie Inc.10-K - BIOVIE INC. (0001580149) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by BioVie Inc.SCHEDULE 13G/A - BIOVIE INC. (0001580149) (Subject)
- SECSEC Form SCHEDULE 13G filed by BioVie Inc.SCHEDULE 13G - BIOVIE INC. (0001580149) (Subject)
- SECSEC Form FWP filed by BioVie Inc.FWP - BIOVIE INC. (0001580149) (Subject)
- SECSEC Form FWP filed by BioVie Inc.FWP - BIOVIE INC. (0001580149) (Subject)
- SECSEC Form FWP filed by BioVie Inc.FWP - BIOVIE INC. (0001580149) (Subject)
- SECAmendment: SEC Form S-1/A filed by BioVie Inc.S-1/A - BIOVIE INC. (0001580149) (Filer)
- SECBioVie Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - BIOVIE INC. (0001580149) (Filer)
- PRBioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s DiseasePatients treated with bezisterim demonstrated statistically significant improvements compared to placebo on both motor and non-motor symptoms, as assessed by MDS-UPDRS1 Parts I, II, and III, as well as a composite endpoint comprising 15 clinically relevant measures. Bezisterim treatment appeared to have a beneficial impact on plasma biomarkers of neurodegeneration and reduced biomarkers of both neuro- and systemic-inflammation. Bezisterim treatment appeared to have a broad, proteome-wide impact, with 283 of 380 proteins shifting in the direction that has been shown to suggest slowing of disease progression. Conference call scheduled for 4:15 p.m. on August 12, 2026, to discuss results. C
- SECAmendment: SEC Form S-1/A filed by BioVie Inc.S-1/A - BIOVIE INC. (0001580149) (Filer)
- SECSEC Form S-1 filed by BioVie Inc.S-1 - BIOVIE INC. (0001580149) (Filer)
- SECSEC Form EFFECT filed by BioVie Inc.EFFECT - BIOVIE INC. (0001580149) (Filer)
BIVI FAQ
6 questionsWhat does BioVie Inc. do?
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and...Where does BIVI stock trade?
BioVie Inc. (BIVI) is listed on NASDAQ.What sector and industry is BIVI in?
BioVie Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BIVI?
BioVie Inc. has had 2 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Overweight with a $700.00 price target on 2022-07-22. Recent price targets range from $700.00 to $2700.00.What companies are similar to BIVI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BIVI side-by-side with any of them on Quantisnow.How can I track BIVI on Quantisnow?
Quantisnow aggregates BioVie Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BIVI to receive live email and push alerts on every new disclosure.